<DOC>
	<DOCNO>NCT01417806</DOCNO>
	<brief_summary>The majority small cell lung cancer ( SCLC ) ( 50-100 % ) express somatostatin receptor ( type 1-5 ) small cell lung cancer express one subtypes . Stimulation SSTR 's lead inhibition angiogenesis cell growth . SOM230 also low level IGF know contribute SCLC proliferation . Topotecan approve second line therapy relapse small cell lung cancer . We hypothesize combination agent yield great antitumor activity .</brief_summary>
	<brief_title>Trial pasireotideLAR Topotecan Relapsed Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description>The primary objective study assess progression-free survival ( PFS ) combination SOM230 topotecan patient SCLC relapse progress front-line chemotherapy cisplatin etoposide . The secondary objective evaluate efficacy safety SOM230 combination topotecan population . The primary end point progression free survival . The secondary objective response rate duration response , overall survival , safety tolerability . Patient eligible study receive topotecan 1.5mg/m2 day 1-5 SOM230 60mg day 1 every 28 day tumor progression toxicity limit treatment . Contrast-enhanced CT scan perform baseline every 2 month ( sooner clinically indicate ) ass response , duration response , time tumor progression Patients allow remain therapy treatment tolerate evidence progression maximum 1 year unacceptable toxicity occur .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Inclusion criterion 1 . Histologically documented SCLC fail one chemotherapy documentation relapse progressive disease . 2 . Measurable evaluable disease CT scan . If evaluable disease measurable disease previously treat , must show sign tumor progression CT. 3 . Karnofsky performance status 80 , Age ≥ 18 year life expectancy ≥12 week 4 . Minimum four week since major surgery , completion radiation chemotherapy 5 . ANC ≥ 1.5 x 109/L , Platelets ≥ 100 x 109/L , Hgb &gt; 9 g/dL . 6 . Serum bilirubin ≤ 2 x upper limit normal ( ULN ) , serum transaminase activity ≤ 3 x ULN , exception serum transaminase ( &lt; 5 x ULN ) patient liver metastasis . Serum creatinine ≤ 1.5 x ULN . 7 . Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN . NOTE : If exceed , patient include initiation appropriate lipid lower medication . 8 . Women childbearing potential must negative serum pregnancy test within 14 day administration first study treatment . Women must lactate . 9 . Signed informed consent participate study must obtain patient fully inform nature potential risk investigator ( his/her designee ) aid write information . Exclusion criterion 1 . Prior topotecan prior octreotide therapy . 2 . Chronic treatment systemic steroid another immunosuppressive agent . 3 . Patients receive immunization attenuate live vaccine study period within 1 week study entry . 4 . Uncontrolled brain leptomeningeal metastasis . 5 . Patients prior concurrent malignancy except follow : adequately treat basal cell squamous cell skin cancer , cancer patient disease free five year . 6 . Patients uncontrolled diabetes mellitus fast plasma glucose &gt; 1.5 ULN.. 7 . Patients symptomatic cholelithiasis . 8 . Patients congestive heart failure , unstable angina , sustain ventricular tachycardia , ventricular fibrillation , clinically significant bradycardia , advanced heart block history acute myocardial infarction within six month precede enrollment . 9 . Patients high risk cardiac arrhythmia define follow : Baseline QTcF &gt; 450 msec History syncope family history idiopathic sudden death long QT syndrome Sustained clinically significant cardiac arrhythmia Risk factor Torsades de Pointes hypokalemia , hypomagnesemia , cardiac failure , clinically significant/symptomatic bradycardia , highgrade AV block Concomitant disease ( ) could prolong QT autonomic neuropathy ( cause diabetes , Parkinson 's disease ) , HIV , cirrhosis , uncontrolled hypothyroidism cardiac failure Concomitant medication ( ) know increase QT interval 10 . Patients take concomitant medication risk prolong QT interval . If patient include study , medication need discontinue 11 . Patients presence active suspect acute chronic uncontrolled infection history immunocompromise , include positive HIV test result 12 . None malignant disease uncontrolled severe impair lung function . 13 . Women pregnant breast feeding , women/men able conceive unwilling practice effective method birth control . ( Women childbearing potential must negative serum pregnancy test within 14 day prior administration pasireotide ) . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study . 14 . Known hypersensitivity somatostatin analogue component pasireotide octreotide LAR formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>small cell lung cancer</keyword>
	<keyword>somatostatin</keyword>
	<keyword>topotecan</keyword>
</DOC>